A5100392932- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- MicroRNA in disease regulation
- Chronic Lymphocytic Leukemia Research
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Cancer-related gene regulation
- Hematopoietic Stem Cell Transplantation
- Epigenetics and DNA Methylation
- RNA Research and Splicing
- RNA Interference and Gene Delivery
- Circular RNAs in diseases
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Immune cells in cancer
- Protein Degradation and Inhibitors
- Blood Coagulation and Thrombosis Mechanisms
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
City of Hope
2016-2025
Beckman Research Institute
2015-2025
City Of Hope National Medical Center
2014-2025
Guangdong Provincial Hospital of Traditional Chinese Medicine
2025
Guangzhou University of Chinese Medicine
2025
Chinese PLA General Hospital
2021-2025
Henan University of Science and Technology
2024
Institute of Hematology & Blood Diseases Hospital
2023
Chinese Academy of Medical Sciences & Peking Union Medical College
2023
The Ohio State University
2023
We characterized leukemia stem cells (LSC) in chronic phase myelogenous (CML) using a transgenic mouse model. LSC were restricted to with long-term hematopoietic cell (LTHSC) phenotype. CML LTHSC demonstrated reduced homing and retention the bone marrow (BM), related decreased CXCL12 expression BM, resulting from increased G-CSF production by cells. Altered cytokine BM was associated selective impairment of normal growth advantage LTHSC. Imatinib (IM) treatment partially corrected...
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends on the requirement for BCR-ABL1 activity CML progenitors. However, quiescent HSCs are TKI resistant and represent a kinase-independent disease reservoir. Here we have shown that persistence leukemic BM requires inhibition tumor suppressor protein phosphatase 2A (PP2A) expression--but not activity--of oncogene. Examination from patients healthy individuals revealed PP2A was suppressed compared...
Inhibition of BCL-2, MCL-1, and BCL-X L eradicates CML stem cells in a mouse model primary blast crisis samples.
Abstract INTRODUCTION With the advancement of disease‐modifying therapies for Alzheimer's disease (AD), validating plasma biomarkers against cerebrospinal fluid (CSF) and positron emission tomography (PET) standards is crucial in both research real‐world settings. METHODS We measured phosphorylated tau (p‐tau)217, p‐tau181, amyloid beta (Aβ)1‐40, Aβ1‐42, neurofilament light chain cohorts. Participants were categorized by brain status using US Food Drug Administration/European Medicines...
Mutations in LMAN1 (ERGIC-53) and MCFD2 are thecauses of a human genetic disorder, combined deficiency coagulation factorV factor VIII. is type 1 transmembrane protein with homology tomannose-binding lectins. soluble EF-hand-containing that isretained the endoplasmic reticulum through its interaction LMAN1. Weshowed endogenous present primarily complex witheach other 1:1 stoichiometry, although not required foroligomerization Using cross-linking-immunoprecipitation assay, wedetected specific...
Targeting the Hedgehog (Hh) pathway represents a potential leukaemia stem cell (LSC)-directed therapy which may compliment tyrosine kinase inhibitors (TKIs) to eradicate LSC in chronic phase (CP) myeloid (CML). We set out elucidate role of Hh signaling CP-CML and determine if inhibition signaling, through smoothened (SMO), was an effective strategy target LSC. Assessment gene protein expression demonstrated that is activated CD34(+) stem/progenitor cells. LDE225 (Sonidegib), small molecule,...
Abstract Induction of reactive oxygen species (ROS), an important process for the cytotoxicity various acute myeloid leukemia (AML) therapies including hypomethylating agents (HMAs), concurrently activates NF‐E2‐related factor 2 (Nrf2) antioxidant response pathway which in turn results induction enzymes that neutralize ROS. In this study, we demonstrated Nrf2 inhibition is additional mechanism responsible marked antileukemic activity AML seen with combination HMAs and venetoclax (ABT‐199)....
The mechanisms responsible for cervical cancer radioresistance are still largely unexplored. present study aimed to identify miRNAs associated with of cells.The radioresistant cell variants were established by repeated selection irradiation. miRNA profiles cells and their corresponding controls analyzed compared using microarray. Differentially expressed confirmed quantitative real-time PCR. Cervical transfected miRNA-specific mimics or inhibitors. Radiosensitivity determined colony-forming...